Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and infectious diseases on people’s lives is why we’re here

Innovation and research

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

A vaccine platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ vaccine has the potential to treat many disease areas, including cancer.

Highlights

Company update on T cell focused COVID-19 vaccine candidate

Read More
05 January 2022

Nykode Therapeutics announces first subject dosed with its T ...

Read More
28 December 2021

Vaccibody AS – Notice of Extraordinary General Meeting

Read More
15 December 2021

New chairman at Nykode Therapeutics as the Company enters ...

Read More
15 December 2021

Minutes of Extraordinary General Meeting

Read More
30 November 2021

Nykode Therapeutics (formerly Vaccibody*)) resolves to issue shares to ...

Read More
24 November 2021

ABGSC Oncology Seminar

Read More
23 November 2021

Nykode Therapeutics company update

Read More
23 November 2021

Nykode Therapeutics (formerly Vaccibody) enters into multi-target license and ...

Read More
23 November 2021